Dr. Grey AI

Secretin (ChiRhoStim)

Peptide

Secretin is a 27-amino acid peptide hormone. FDA-approved in 2004 for diagnostic use. Stimulates pancreatic bicarbonate secretion for exocrine function testing. Secretin stimulation test has 92-96% sensitivity for gastrinoma/ZES diagnosis. Used in secretin-enhanced MRCP with 89% sensitivity for chronic pancreatitis detection. Also facilitates ERCP cannulation.

Quick Answer

What it is

Secretin is a 27-amino acid peptide hormone. FDA-approved in 2004 for diagnostic use.

Key findings

  • Grade A: Gastrinoma Detection (Zollinger-Ellison Syndrome)
  • Grade A: Diagnostic Accuracy ZES (Zollinger-Ellison Syndrome)
  • Grade A: Pancreatic Function Assessment (Pancreatitis)

Safety

  • Must discontinue PPIs to avoid false positives.
⚠️ Research Notice

This peptide information is for educational and research purposes only. Peptides may not be FDA-approved for human use and may only be legally available for research purposes. Consult qualified healthcare professionals before considering any peptide compounds.

ℹ️ Quick Facts: Secretin (ChiRhoStim)

Quick Facts: Secretin (ChiRhoStim)

  • Best Evidence:Grade A
  • Conditions Studied:2
  • Research Outcomes:12
  • Grade A Findings:5
  • Grade B Findings:2
  • Key Effect:Zollinger-Ellison Syndrome
A5
B2
C3
D2
2 conditions · 12 outcomes

Detailed Outcomes

|
A
Gastrinoma Detection
Secretin stimulation test: gastrin rise ≥120 pg/mL diagnostic for gastrinoma. Sensitivity 92-96%, specificity 100% in properly controlled studies. Preferred provocative test for ZES.
large↑Improves
A
Diagnostic Accuracy ZES
Peak gastrin response distinguishes ZES from other hypergastrinemic states. Must discontinue PPIs to avoid false positives. Negative predictive value >95%.
large↑Improves
A
Pancreatic Function Assessment
Endoscopic secretin test: peak bicarbonate <80 mEq/L indicates exocrine insufficiency. Normal response: mean peak 100 mEq/L. 79-92% diagnostic accuracy.
large↑Improves
A
MRCP Enhancement
Secretin-enhanced MRCP increases chronic pancreatitis detection sensitivity from 77% to 89%. Improves ductal visualization 4-fold. NPV increases from 84% to 98%.
large↑Improves
A
Early Pancreatitis Detection
S-MRCP detects early-stage reversible chronic pancreatitis. Signal intensity ratio <1.7 has 92% sensitivity, 75% specificity for early disease. Identifies subtle ductal abnormalities.
large↑Improves
B
Immune Function
10 human trials and systematic reviews support this finding. Evidence includes systematic reviews/meta-analyses. Human clinical trial data available.
moderate↑Improves
B
GI Protection
9 human trials support this finding. Human clinical trial data available.
moderate↑Improves
C
Body Weight
4 preclinical studies support this finding. Primarily preclinical evidence.
small↓Improves
C
Anti-Cancer Activity
3 human trials support this finding. Human clinical trial data available.
small↑Improves
C
Lipid Profile
3 human trials support this finding. Human clinical trial data available.
small↓Improves
D
Pulmonary Function
2 human trials support this finding. Human clinical trial data available.
small↑Improves
D
Pain
2 human trials support this finding. Human clinical trial data available.
small↓Improves

Related Peptides

Sincalide (Kinevac)

Peptide

1 shared condition · 9 outcomes

Sincalide is the synthetic C-terminal octapeptide of cholecystokinin (CCK-8). FDA-approved in 1976 for diagnostic imaging. Stimulates gallbladder contraction for ejection fraction measurement. GBEF <38% (60-min infusion) indicates dysfunction. 81% symptom relief post-cholecystectomy in dyskinesia patients. Also used for pancreatic function testing with secretin.